Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies

References

• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14:2014296. PMID: 35030985. doi:10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185:2789–16. PMID: 35868279. doi:10.1016/j.cell.2022.05.029.
   PubMed Web of Science ®Google Scholar
• Lou H, Cao X. Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun (Lond). 2022;42(9):804–27. PMID: 35822503. doi:10.1002/cac2.12330.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256–65. PMID: 20400861. doi:10.4161/mabs.2.3.11641.
   PubMed Web of Science ®Google Scholar
• Xue L, Fiscella M, Rajadhyaksha M, Goyal J, Holland C, Gorovits B, Morimoto A. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. Aaps J. 2013;15(3):852–55. PMID: 23620231. doi:10.1208/s12248-013-9492-4.
   PubMed Web of Science ®Google Scholar
• Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014 Date.
   Google Scholar
• Immunogenicity information in human prescription therapeutic protein and select drug product labeling —Guidance for industry. 2022 Date.
   Google Scholar
• Kumar SC, DelCarpini JA, Qu Q, Kane M, Gorovits B. Mitigation of pre-existing antibodies to a biotherapeutic in non-clinical species when establishing anti-drug antibody assay cutpoint. Aaps J. 2017;19(1):313–19. PMID: 27873117. doi:10.1208/s12248-016-0011-2.
   PubMed Web of Science ®Google Scholar
• Schneider AK, Vainshtein I, Roskos LK, Chavez C, Sun B, Liang M. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox. J Immunol Methods. 2016;435:68–76. PMID: 27220271. doi:10.1016/j.jim.2016.05.007.
   PubMed Web of Science ®Google Scholar
• Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—Harmonized terminology and tactical recommendations. Aaps J. 2014;16(4):658–73. PMID: 24764037. doi:10.1208/s12248-014-9599-2.
   PubMed Web of Science ®Google Scholar
• Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang ASMW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T. Anti-hinge antibodies recognize IgG Subclass– and protease-restricted neoepitopes. J Immunol. 2017;198(1):82–93. PMID: 27864476. doi:10.4049/jimmunol.1601096.
   PubMed Web of Science ®Google Scholar
• Bivi N, Moore T, Rodgers G, Denning H, Shockley T, Swearingen CA, Gelfanova V, Calderon B, Peterson DA, Hodsdon ME, et al. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. MAbs. 2019;11(5):861–69. PMID: 31099718. doi:10.1080/19420862.2019.1612699.
   PubMed Web of Science ®Google Scholar
• BEOVU® (brolucizumab-dbll) prescribing information. Available Date: https://www.novartis.com/us-en/sites/novartis_us/files/beovu.pdf (accessed December 24).
   Google Scholar
• Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, et al. Autoantibodies to Variable Heavy (VH) chain ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33(7):1192–203. PMID: 23832582. doi:10.1007/s10875-013-9915-0.
   PubMed Web of Science ®Google Scholar
• Lin J, Lee SL, Russell AM, Huang RF, Batt MA, Chang SS, Ferrante A, Verdino P, Henry KA. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLos One. 2021;16(7):e0254944. PMID: 34297759. doi:10.1371/journal.pone.0254944.
   PubMed Web of Science ®Google Scholar
• Cordy JC, Morley PJ, Wright TJ, Birchler MA, Lewis AP, Emmins R, Chen YZ, Powley WM, Bareille PJ, Wilson R, et al. Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1. Clin Exp Immunol. 2015;182(2):139–48. PMID: 26178412. doi:10.1111/cei.12680.
   PubMed Web of Science ®Google Scholar
• Nieba L, Honegger A, Krebber C, Pluckthun A. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 1997;10(4):435–44. PMID: 9194169. doi:10.1093/protein/10.4.435.
   PubMedGoogle Scholar
• Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, Alvarez JC, Volkin DB. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J Pharm Sci. 2011;100(3):1009–21. PMID: 21280052. doi:10.1002/jps.22350.
   PubMed Web of Science ®Google Scholar
• Haverick M, Mengisen S, Shameem M, Ambrogelly A. Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. MAbs. 2014;6:852–58. PMID: 24751784. doi:10.4161/mabs.28693.
   PubMed Web of Science ®Google Scholar
• Temel DB, Landsman P, Brader ML. Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies: differential scanning calorimetry, isothermal chemical denaturation, and intrinsic fluorescence with concomitant static light scattering. Methods Enzymol. 2016;567:359–89. PMID: 26794361. doi:10.1016/bs.mie.2015.08.029.
   PubMed Web of Science ®Google Scholar
• Egan TJ, Diem D, Weldon R, Neumann T, Meyer S, Urech DM. Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs. 2017;9:68–84. PMID: 27786600. doi:10.1080/19420862.2016.1248012.
   PubMed Web of Science ®Google Scholar
• Borras L, Urech D. 2009. WO 2009/155725.
   Google Scholar
• Borras L, Gunde T, Urech D. 2011. WO 2011/075861.
   Google Scholar
• Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenet. 2015;67:641–50. PMID: 26416257. doi:10.1007/s00251-015-0873-y.
   PubMed Web of Science ®Google Scholar
• Andreatta M, Trolle T, Yan Z, Greenbaum JA, Peters B, Nielsen M, Berger B. An automated benchmarking platform for MHC class II binding prediction methods. Bioinf. 2018;34(9):1522–28. PMID: 29281002. doi:10.1093/bioinformatics/btx820.
   PubMed Web of Science ®Google Scholar
• Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenet. 2011;63:325–35. PMID: 21305276. doi:10.1007/s00251-011-0513-0.
   PubMed Web of Science ®Google Scholar
• Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, Wasserman SI, Weiskopf D, McKinney DM, Chung JL, et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol. 2010;185(2):943–55. PMID: 20554959. doi:10.4049/jimmunol.1000405.
   PubMed Web of Science ®Google Scholar
• Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol. 2003;325(3):531–53. PMID: 12498801. doi:10.1016/s0022-2836(02)01237-8.
   PubMed Web of Science ®Google Scholar
• Honegger A, Pluckthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol. 2001;309(3):657–70. PMID: 11397087. doi:10.1006/jmbi.2001.4662.
   PubMed Web of Science ®Google Scholar
• Kroner F, Hubbuch J. Systematic generation of buffer systems for pH gradient ion exchange chromatography and their application. J Chromatogr A. 2013;1285:78–87. PMID: 23489486. doi:10.1016/j.chroma.2013.02.017.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL Design of therapeutic proteins with enhanced stability. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:11937–42. doi:10.1073/pnas.0904191106. PMID: 19571001.
   Google Scholar
• BIOVIA, Dassault Systèmes, Discovery Studio, v20.1.0.19295, San Diego: Dassault Systèmes, 2019.
   Google Scholar
• BIOVIA, Dassault Systèmes, Discovery Studio, v22.1.021297, San Diego: Dassault Systèmes, 2021.
   Google Scholar
• Black SD, Mould DR. Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal Biochem. 1991;193(1):72–82. PMID: 2042744. doi:10.1016/0003-2697(91)90045-u.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Brooks CL, Mackerell AD Jr., Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30(10):1545–614. PMID: 19444816. doi:10.1002/jcc.21287.
   PubMed Web of Science ®Google Scholar
• Kellogg EH, Leaver-Fay A, Baker D. Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins Struct Funct Bioinf. 2011;79(3):830–38. PMID: 21287615. doi:10.1002/prot.22921.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res. 2000;28(1):235–42. PMID: 10592235. doi:10.1093/nar/28.1.235.
   PubMed Web of Science ®Google Scholar
• Kemmish H, Fasnacht M, Yan L, Gill AC. Fully automated antibody structure prediction using BIOVIA tools: validation study. PLos One. 2017;12(5):e0177923. PMID: 28542300. doi:10.1371/journal.pone.0177923.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. PMID: 15264254. doi:10.1002/jcc.20084.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30(1):70–82. PMID: 32881101. doi:10.1002/pro.3943.
   PubMed Web of Science ®Google Scholar